Suppr超能文献

前列腺切除术后辅助放疗与早期挽救性放疗的长期结果:一项大型单机构研究经验

Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience.

作者信息

Buscariollo Daniela L, Drumm Michael, Niemierko Andrzej, Clayman Rebecca H, Galland-Girodet Sigolene, Rodin Danielle, Feldman Adam S, M Dahl Douglas, McGovern Francis J, F Olumi Aria, Eidelman Alec, Shipley William U, Zietman Anthony L, Efstathiou Jason A

机构信息

Harvard Radiation Oncology Program, Massachusetts General Hospital, Boston, Massachusetts.

Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

Pract Radiat Oncol. 2017 Mar-Apr;7(2):e125-e133. doi: 10.1016/j.prro.2016.10.010. Epub 2016 Oct 19.

Abstract

PURPOSE

The purpose of this study was to evaluate freedom from biochemical failure (FFBF), freedom from androgen deprivation therapy (FFADT), freedom from distant metastases (FFDM), and overall survival (OS) after adjuvant radiation therapy (ART) versus early salvage radiation therapy (ESRT) in men with prostate cancer and adverse pathologic features (pT3 and/or positive surgical margins).

METHODS AND MATERIALS

Of 718 patients consecutively treated with postoperative radiation therapy (RT) for prostate cancer between 1992 and 2013, we retrospectively identified 171 men receiving ART and 230 receiving ESRT (RT delivered at a prostate-specific antigen level ≤0.5 ng/mL) who had adverse pathologic features. Postirradiation FFBF (BF was defined as prostate-specific antigen level rise to ≥0.2 ng/mL), FFADT, FFDM, and OS were compared using Kaplan-Meier and Cox regression methods. Propensity score (PS)-matching was performed to estimate treatment effects while accounting for covariates predicting treatment allocation.

RESULTS

Median follow-up was 7.4 and 8.0 years for patients treated with ART and ESRT, respectively. Ten-year FFBF (69% vs 56%, P = .003) and 10-year FFADT (88% vs 81%, P = .046) rates were higher after ART; however, FFDM and OS did not significantly differ. After PS-matching, ART was associated with improved FFBF (P < .0001), FFADT (P = .0001), and FFDM (P = .02). Findings were confirmed in multivariable analyses in unmatched and PS-matched cohorts. Sensitivity analyses showed that FFBF benefit associated with ART lost statistical significance only after 38% of ART patients were assumed to have been cured by surgery and excluded from the model. This corresponds to the upper bound of patients with adverse pathologic features who did not recur after observation in prior randomized trials.

CONCLUSIONS

Postoperative RT confers excellent long-term cancer control. These results suggest ART may be associated with improved FFBF, FFADT, and FFDM, but comparable OS. Given the retrospective study design, these findings should be interpreted with caution. Optimal timing of postoperative RT further awaits results of ongoing trials.

摘要

目的

本研究旨在评估辅助放疗(ART)与早期挽救性放疗(ESRT)对具有不良病理特征(pT3和/或手术切缘阳性)的前列腺癌男性患者的无生化失败生存期(FFBF)、无雄激素剥夺治疗生存期(FFADT)、无远处转移生存期(FFDM)及总生存期(OS)的影响。

方法与材料

在1992年至2013年间连续接受前列腺癌术后放疗(RT)的718例患者中,我们回顾性确定了171例接受ART和230例接受ESRT(在前列腺特异性抗原水平≤0.5 ng/mL时进行RT)且具有不良病理特征的男性患者。采用Kaplan-Meier法和Cox回归方法比较放疗后的FFBF(BF定义为前列腺特异性抗原水平升至≥0.2 ng/mL)、FFADT、FFDM和OS。进行倾向评分(PS)匹配以估计治疗效果,同时考虑预测治疗分配的协变量。

结果

接受ART和ESRT治疗的患者中位随访时间分别为7.4年和8.0年。ART后的10年FFBF(69%对56%,P = 0.003)和10年FFADT(88%对81%,P = 0.046)率更高;然而,FFDM和OS无显著差异。PS匹配后,ART与改善的FFBF(P < 0.0001)、FFADT(P = 0.0001)和FFDM(P = 0.02)相关。在未匹配和PS匹配队列的多变量分析中证实了这些发现。敏感性分析表明,仅在假设38%的ART患者已通过手术治愈并从模型中排除后,与ART相关的FFBF益处才失去统计学意义。这对应于既往随机试验中观察后未复发的具有不良病理特征患者的上限。

结论

术后放疗可实现出色的长期癌症控制。这些结果表明ART可能与改善的FFBF、FFADT和FFDM相关,但OS相当。鉴于本研究为回顾性设计,这些发现应谨慎解释。术后放疗的最佳时机有待正在进行的试验结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验